Related references
Note: Only part of the references are listed.Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?
Francesco Panza et al.
ANNALS OF NEUROLOGY (2019)
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise
Christopher H. van Dyck
BIOLOGICAL PSYCHIATRY (2018)
Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead
Petr Novak et al.
FRONTIERS IN NEUROSCIENCE (2018)
The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model
Randall J. Bateman et al.
ALZHEIMERS & DEMENTIA (2017)
Immunotherapeutic Approaches Targeting Amyloid-beta, alpha-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders
Elvira Valera et al.
NEUROTHERAPEUTICS (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
The A4 Study: Stopping AD Before Symptoms Begin?
Reisa A. Sperling et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Neuropathology after active A beta 42 immunotherapy: implications for Alzheimer's disease pathogenesis
Delphine Boche et al.
ACTA NEUROPATHOLOGICA (2010)
Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathology
Alberto Serrano-Pozo et al.
BRAIN (2010)
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
S Gilman et al.
NEUROLOGY (2005)
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
AJ Bayer et al.
NEUROLOGY (2005)
Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease
E Masliah et al.
NEUROLOGY (2005)
Share Paper
